Drug Information Related to Palonosetron Hydrochloride
Back
01. MGI PHARMA Summarizes Data Presented at the 2007 American Society of ....
--Dacogen([R]) Activity in Older Patients with AML and in
Refractory ALL Patients Presented--
--Differentiation of the molecular interaction of Aloxi([R]) with
the 5-HT3 Receptor Reported--
--Results of a Survival Analysis of Glioblastoma Patients Treated
w...
02. MGI PHARMA Announces Initiation of Aquavan(R) Injection Pivotal Progra...
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN), an oncology- and acute care- focused biopharmaceutical company, today announced the initiation of the Aquavan(R) (fospropofol disodium di·so·di·um (d-sd-) Injection pivotal program. This program consists of two r...
03. Dacogen(TM) (Decitabine) for Injection Data Presented at the American ...
ORLANDO, Fla. -- MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute care, today provided a summary of the Dacogen[TM] (decitabine decitabine /de·ci·ta·bine/ (DAC) (de-si´tah-ben?) a cytotoxic compound used as an antineo...
04. MGI PHARMA and HELSINN Announce Submission of Supplemental New Drug .....
-- Oral Formulations of 5HT3 Receptor Antagonists Represent
Approximately 10% of the Day-of-Chemotherapy Market --
MINNEAPOLIS & LUGANO, Switzerland -- MGI PHARMA, INC.
(Nasdaq:MOGN), a biopharmaceutical company focused in oncology and acute
care, and its ...
05. MGI PHARMA Reports Third Quarter Financial Results. - Free Online Libr...
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN):--Sales of Aloxi(R) injection total $47.6 million for the third
quarter--Aloxi(R) injection sales guidance increased for FY2004--Dacogen(TM), ZYCOS, and Aesgen transactions completedMGI PHARMA, INC. (Nasdaq:MOGN) today an...
06. Aloxi(R) Phase 3 Data for Post Operative Nausea and Vomiting (PONV ......
Successful Aloxi([R]) Phase 3 Results in PONV Presented
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN), a biopharmaceutical
company focused in oncology and acute care, and its partner HELSINN
HEALTHCARE SA, a privately owned Swiss pharmaceutical group, today
an...
07. MGI PHARMA Reports Second Quarter Financial Results. - Free Online Lib...
MINNEAPOLIS -- Second Quarter Aloxi(TM) Injection Sales Total $37.1
Million; Aloxi(TM) Injection Guidance Revised Upwards to $140 to $150
Million for 2004MGI PHARMA, INC. (Nasdaq:MOGN) today announced that total revenue
for the second quarter of 2004 was $47.9 mill...
08. MGI PHARMA Reports Fiscal 2003 Results and Provides 2004 Financial ......
Business EditorsMINNEAPOLIS--(BUSINESS WIRE)--Feb. 11, 2004MGI PHARMA, INC. (Nasdaq:MOGN) today reported a 2003 net loss of
$61.9 million, or $2.23 per share, and 2003 sales revenue of $39.9
million, including Aloxi(TM) (palonosetron hydrochloride) injection
sales ...
09. MGI PHARMA Reports First Quarter 2004 Financial Results. - Free Online...
Business EditorsMINNEAPOLIS--(BUSINESS WIRE)--April 14, 2004First Quarter Aloxi(TM) Injection Sales Total $18.6 Million;Aloxi(TM) Injection Guidance RevisedUpwards to $115 to $130 Million for 2004MGI PHARMA, INC. (Nasdaq:MOGN) today announced that total revenue
for t...
10. MGI PHARMA Updates Outlook for First Quarter. - Free Online Library...
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN), an oncology- and acute care-focused biopharmaceutical company, today announced that for the first quarter of 2006, it expects total revenue to be approximately $78 million and loss per share in the range of ($0.03) to ($...
11. FDA Approves Aloxi(R) (Palonosetron HCl) Injection for Prevention of ....
LUGANO, Switzerland, March 3 /PRNewswire/ -- Helsinn Healthcare SA, a Swiss pharmaceutical group, together with its partner Eisai Corporation of North America and Eisai's U.S. subsidiary, MGI Pharma, Inc., today announced that the U.S. Food and Drug Administrat...
12. MGI PHARMA Announces That Aloxi Qualifies for Pass-Through Status ......
Business Editors/Health/Medical Writers
...
13. MGI PHARMA Brings Aloxi Message Directly to Patients and Caregivers .....
MINNEAPOLIS -- MGI PHARMA, INC. today announced the launch of a campaign targeted at patients with cancer experiencing chemotherapy-induced nausea and vomiting (CINV). The "Yes to Control" Patient Program features resources for patients and their caregivers ...
14. Aloxi® Phase 3 Data for Post Operative Nausea and Vomiting Presented ...
Successful Aloxi([R]) Phase 3 Results in PONV Presented
...
15. MGI PHARMA and HELSINN Announce Aloxi® sNDA Approval Allowing for ......
Approximately Ten Percent of 5-HT3 Receptor Antagonist Doses Administered for CINV are Associated With Multi-Day Chemotherapy
...
16. MGI PHARMA Summarizes Recent Aloxi Data Presentations Business Wire .....
Business Editors/Health/Medical Writers
...
17. Helsinn/Biovitrum Sign License Pact For Aloxi Marketing | Worldwide .....
Helsinn and Biovitrum enter a license agreement for Nordic marketing of Aloxi, a drug that prevents nausea and vomiting in cancer patients
...
18. MGI PHARMA to Present at the Merrill Lynch Global Drug, Biotech and .....
MINNEAPOLIS -- MGI PHARMA, INC. (Nasdaq:MOGN) today announced that it will present at the Merrill Lynch Global Drug, Biotech and Medical Devices Conference 2004 on September 23, 2004 at 3:20 p.m. British Summer Time. Lonnie Moulder, president and chief executive offic...
19. MGI PHARMA and HELSINN Announce Aloxi sNDA for PONV Accepted for Revie...
PDUFA Date of March 4, 2008 Established
...
